| AID | Autoimmune diseases |
| ANA | Antinuclear antibody |
| Anti-CCP | Anti-cyclic citrullinated peptide |
| ASIA | Autoimmune/Inflammatory syndrome induced by adjuvants |
| ASMA | Anti-smooth muscle antibody |
| CI | Confidence interval |
| CPI | Check-point inhibitors |
| CTLA | Cytotoxic T lymphocyte antigen |
| ENA | Extractable nuclear antigens |
| HBV | Hepatitis B virus |
| HLA | Human leukocyte antigen |
| ICIs | Immune checkpoint inhibitors |
| IFN-γ | Interferon gamma |
| IL | Interleukin |
| irAEs | Immune-related adverse events |
| NZB | New Zealand black |
| NZM | New Zealand mixed |
| OR | Odds ratio |
| PD-1 | Programmed cell death receptor-1 |
| PFS | Progression free survival |
| RF | Rheumatoid factor |
| SADs | Systemic autoimmune diseases |
| SBIs | Silicone breast implants |
| SFN | Small fiber neuropathy |
| SIIS | Silicone implant incompatibility syndrome |
| SS | Sjogren’s syndrome |
| SSc | Systemic sclerosis |
| TGF-β | Transforming growth factor β |
| Th | T helper lymphocytes |
| TLR-4 | Toll-like receptor 4 |
| TNF-α | Tumor necrosis factor α |
| UCTD | Undifferentiated connective tissue disease |